EarningsQ4 2025 Earnings Report
DE:26CA Q4 2025 EPS Results
Actual EPS-€0.05
Consensus EPS-€0.07
Beat/MissBeat by +€0.02
One Year Ago EPS-€0.08
DE:26CA Q4 2025 Revenue Results
Actual Revenue€34.17M
Expected Revenue€34.23M
Beat/MissMissed by -€67.82K
YoY Revenue Growth+406.95%
Earnings Announcement Details
QuarterQ4 2025
Date03/03/2026
TimeBefore Open
Conference CallTuesday, March 3, 2026
DE:26CA Upcoming Earnings
ImmunityBio's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q4 2025 Earnings Call Audio
DE:26CA Q4 2025 Earnings Call
0:00 / 0:00
Q4 2025 Earnings Slide Deck
No slide deck is available for this earnings event.
Q4 2025 Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted strong commercial traction for ANKTIVA with very large year-over-year revenue and unit growth, multiple regulatory milestones (including EU conditional authorization and Saudi first-in-world lung cancer approval), robust enrollment and promising clinical signals across randomized and single-arm QUILT programs, and strategic commercial partnerships and manufacturing initiatives. Offsetting these positives are substantial operating losses and cash burn, significant balance sheet liabilities, continued high R&D investment (including a one-time $14M equipment write-off), and some regulatory delays and market-access complexity in certain cohorts and geographies. Overall, the company is demonstrating clear commercial momentum and clinical progress but remains capital-intensive and faces execution and regulatory risks as it scales internationally.Company Guidance
Transformational Revenue Growth for ANKTIVA
Full-year net product revenue for ANKTIVA was $113.0M in FY2025 versus $14.1M in FY2024, a 700% year-over-year increase; unit sales volume increased ~750% year-over-year, and Q4 revenue of $38.3M represented a 20% sequential increase vs Q3, indicating accelerating commercial adoption.
Rapid Global Regulatory and Commercial Expansion
ANKTIVA authorized in 33 countries and 4 major jurisdictions (U.S., U.K., Saudi Arabia, European Union) within ~2 years of initial FDA approval; European Commission granted conditional marketing authorization in Feb 2026 (EU27 + Iceland, Norway, Liechtenstein).
Key Regional Approvals and Partnerships
Saudi FDA granted approvals for ANKTIVA in BCG-unresponsive NMIBC and conditional approval in combination with checkpoint inhibitors for metastatic NSCLC (first worldwide lung cancer authorization); commercial partnerships: Accord Healthcare for EU/U.K. distribution (deploying 100+ personnel), Biopharma and Cigalah for Middle East/North Africa, Irish and Saudi subsidiaries established.
Strong Clinical Program Readouts and Enrollment Milestones
QUILT-2.005 (BCG-naive NMIBC) fully enrolled 366 patients; interim results showed 6-month complete response (CR) 85% (ANKTIVA+BCG) vs 57% (BCG alone) and 9-month CR 84% vs 52% (statistically significant at interim). QUILT-3.032 Cohort A (BCG-unresponsive CIS ± papillary) reported 71% CR with duration extending beyond 53 months; Cohort B (papillary) met endpoints: 12‑month disease-free 58%, 24‑month 52%, 36‑month disease-specific survival 96% and ~82% bladder preservation.
Commercial Evidence of Physician Adoption
Company reported repeat prescribing behavior, uptake across community urology practices and academic centers, and generation of real-world evidence supporting routine use in BCG-unresponsive NMIBC; majority of FY2025 ANKTIVA revenue driven by U.S. commercial performance.
Progress on Manufacturing and Novel Platforms
Advancing NANT Leonardo AI-driven robotic cellular manufacturing (Dunkirk, NY) for scalable NK/CAR-NK and m-ceNK production; introduced askIB, an internal AI platform to integrate LLMs and analytics across R&D, manufacturing, and operations.
Expanded Access and Supply Response for BCG Shortage
FDA-authorized expanded access program for recombinant BCG to address longstanding global shortage: ~100 clinical sites active/activating, ~580 patients dosed as of Feb 2026 and several thousand doses delivered, supporting both monotherapy and combination use with ANKTIVA.
Narrowing Net Loss and Active Pipeline Investment
Full-year net loss attributable to common stockholders narrowed to $351.4M in 2025 from $413.6M in 2024 (improvement of ~$62.2M, ~15% reduction) while continuing aggressive R&D investment across multiple platforms (ANKTIVA combos, CAR-NK, DNA vaccine).
DE:26CA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed